Abstract
The clinical value of systemic antifungal medications for onychomycosis using F-RVCZ has been shown in patients of 75 years or younger. However, its value for elderly patients has not been investigated. The purpose of this research is to clarify the value of this drug in patients of 75 years or older.
A retrospective analysis of clinical investigation was conducted in 49 elderly patients (> or =75 years old) with dermatophyte onychomycosis who were treated by F-RVCZ (100 mg RVCZ) p.o. once daily for 12 weeks. At 48-60 weeks after initiation of treatment, a complete cure was obtained in 16 of 23 patients (69%) and at 24-60weeks, a marked clinical improvement was obtained in 44 of 48 patients (93%). The major adverse reactions included laboratory abnormalities (n=4), chest discomfort (n=1) and gastrointestinal disorders (n=4) with no severe symptoms, suggesting good tolerability.
F-RVCT appears to be a clinically useful drug for the treatment of onychomycosis for elderly patients.
